Thiabendazole for the Treatment of Strongyloidiasis in Patients with Hematologic Malignancies
Open Access
- 1 September 2000
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 31 (3) , 821-822
- https://doi.org/10.1086/314023
Abstract
A total of 21 patients with hematologic malignancies were given thiabendazole for treatment of strongyloidiasis. Fifteen patients were cured. Since there were no relapses, it is unlikely that maintenance therapy has a role in the management of strongyloidiasis in this population of patients.Keywords
This publication has 8 references indexed in Scilit:
- Strongyloidiasis and Infection Due to Human Immunodeficiency Virus: 25 Cases at a Brazilian Teaching Hospital, Including Seven Cases of Hyperinfection SyndromeClinical Infectious Diseases, 1999
- StrongyloidiasisClinical Infectious Diseases, 1996
- Strongyloidiasis in Patients with Hematologic MalignanciesClinical Infectious Diseases, 1995
- Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 casesTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- A Randomized Trial of Single- and Two-Dose Ivermectin versus Thiabendazole for Treatment of StrongyloidiasisThe Journal of Infectious Diseases, 1994
- Treatment of Strongyloides stercoralis Hyperinfection Syndrome with Thiabendazole Administered per RectumClinical Infectious Diseases, 1993
- Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectivenessTransactions of the Royal Society of Tropical Medicine and Hygiene, 1982
- Diagnosis of strongyloidiasis: Importance of Baermann's methodDigestive Diseases and Sciences, 1961